Literature DB >> 25377698

Draft Genome Sequence of Bacillus coagulans GBI-30, 6086, a Widely Used Spore-Forming Probiotic Strain.

Luigi Orrù1, Elisa Salvetti2, Luigi Cattivelli1, Antonella Lamontanara1, Vania Michelotti1, Vittorio Capozzi3, Giuseppe Spano3, David Keller4, Howard Cash4, Alessia Martina2, Sandra Torriani5, Giovanna E Felis2.   

Abstract

Bacillus coagulans GBI-30, 6086 is a safe strain, already available on the market, and characterized by certified beneficial effects. The draft genome sequence presented here constitutes the first pillar toward the identification of the molecular mechanisms responsible for its positive features and safety.
Copyright © 2014 Orrù et al.

Entities:  

Year:  2014        PMID: 25377698      PMCID: PMC4223449          DOI: 10.1128/genomeA.01080-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Bacillus coagulans strain GBI-30, 6086 is a safe, spore-forming strain, as testified by the GRAS (Generally Recognized As Safe) status received in 2012 from the United States FDA; the strain is authorized for human consumption and already available in a wide selection of functional foods or as dietary supplement (1). This strain is characterized by certified beneficial effects in gastrointestinal disorders, such as irritable bowel syndrome, intestinal gas, and colitis (2, 3, 4, 5); in rheumatoid arthritis (6); and in common viral infections of the respiratory tract (7). As a sporeformer, B. coagulans GBI-30, 6086 can be incorporated into foods, where it can survive the mild heat-treatments used for sterilization andwithstand the harsh conditions of the gastrointestinal tract, i.e., the low pH of the gastric barrier (8). Here we report the draft genome sequence of B. coagulans GBI-30, 6086 in order to unveil the genetic basis of its safety and probiosis. To the best of our knowledge, this is the first published fully assembled genome of a commercial B. coagulans probiotic strain. The whole-genome sequencing was performed using the Illumina GAIIx platform at CRA-Genomics Research Centre (Piacenza, Italy) with a paired-end library; the reads were de novo assembled using the CLC Genomic Workbench version 7.0. The genome sequence was annotated by the NCBI Prokaryotic Genomes Annotation Pipeline. A total of 14,500,000 paired-end reads of 110-bp length on average (genome coverage of 840×) were assembled into 224 contigs (N50 length of 44,706 bp), with the largest assembled contig of 125,999-bp length. The draft genome consists of 3,458,655 bp with GC % content of 46.38. A total of 3,373 genes were predicted, of which 3,197 are coding sequences (CDS), 18 are rRNAs, and 82 are tRNAs; 79 were identified to be pseudogenes, and 1 was identified as ncRNA. The genome also contains 3 CRISPR arrays, which could be involved as a defense mechanism toward foreign genetic elements (9). The strain is predicted to encode for about 500 proteins involved in central carbohydrate metabolism, including glycolysis, pentose phosphate, and xylose utilization pathways (9, 10). As expected, about 80 genes regarding dormancy and sporulation were annotated, in particular, spore DNA protection, sporulation mechanisms, spore core dehydration, and spore germination. Furthermore, the genome contains determinants involved in the adhesion (i.e., fibronectin- and mucus-binding proteins) and active metabolism in the host (as a biotin biosynthesis pathway). The complete genome of B. coagulans GBI-30, 6086 obtained in the present study will contribute to a wider and deeper insight into the safety features of this strain, and the comparative genomic analysis with other Bacillus strains genomes (11, 12, 13) might shed new light on the molecular mechanisms at the basis of its probiotic and beneficial properties.

Nucleotide sequence accession numbers.

This whole-genome shotgun project has been deposited in DDBJ/EMBL/GenBank under the accession number JPSK00000000. The version described in this paper is the first version, JPSK01000000.
  13 in total

Review 1.  Bacillus coagulans: Monograph.

Authors:  Julie S Jurenka
Journal:  Altern Med Rev       Date:  2012-03

Review 2.  Bacillus probiotics.

Authors:  Simon M Cutting
Journal:  Food Microbiol       Date:  2010-03-24       Impact factor: 5.516

3.  Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.

Authors:  B J Dolin
Journal:  Methods Find Exp Clin Pharmacol       Date:  2009-12

4.  Screening for bacillus isolates in the broiler gastrointestinal tract.

Authors:  Teresa M Barbosa; Cláudia R Serra; Roberto M La Ragione; Martin J Woodward; Adriano O Henriques
Journal:  Appl Environ Microbiol       Date:  2005-02       Impact factor: 4.792

5.  Genome sequence of the thermophile Bacillus coagulans Hammer, the type strain of the species.

Authors:  Fei Su; Fei Tao; Hongzhi Tang; Ping Xu
Journal:  J Bacteriol       Date:  2012-11       Impact factor: 3.490

6.  Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.

Authors:  Larysa Hun
Journal:  Postgrad Med       Date:  2009-03       Impact factor: 3.840

7.  A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms.

Authors:  Douglas S Kalman; Howard I Schwartz; Patricia Alvarez; Samantha Feldman; John C Pezzullo; Diane R Krieger
Journal:  BMC Gastroenterol       Date:  2009-11-18       Impact factor: 3.067

8.  Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial.

Authors:  David R Mandel; Katy Eichas; Judith Holmes
Journal:  BMC Complement Altern Med       Date:  2010-01-12       Impact factor: 3.659

9.  Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice.

Authors:  Leo R Fitzpatrick; Jeffrey S Small; Wallace H Greene; Kelly D Karpa; Sean Farmer; David Keller
Journal:  Gut Pathog       Date:  2012-10-22       Impact factor: 4.181

10.  Genomic analysis of thermophilic Bacillus coagulans strains: efficient producers for platform bio-chemicals.

Authors:  Fei Su; Ping Xu
Journal:  Sci Rep       Date:  2014-01-29       Impact factor: 4.379

View more
  4 in total

1.  Potential probiotic attributes of a new strain of Bacillus coagulans CGMCC 9951 isolated from healthy piglet feces.

Authors:  Shao-Bin Gu; Li-Na Zhao; Ying Wu; Shi-Chang Li; Jian-Rui Sun; Jing-Fang Huang; Dan-Dan Li
Journal:  World J Microbiol Biotechnol       Date:  2015-03-10       Impact factor: 3.312

2.  The Step of Incorporation of Bacillus coagulans GBI-30 6086 Into "requeijão cremoso" Processed Cheese Does Not Affect Metabolic Homeostasis of Rats.

Authors:  Mariana B Soares; Valfredo A Santos-Junior; E R Tavares Filho; Pablo C B Lollo; Priscila N Morato; Jaime Amaya-Farfan; Eliene P R Pereira; Celso F Balthazar; Adriano G Cruz; Rafael C R Martinez; Anderson S Sant'Ana
Journal:  Front Microbiol       Date:  2019-10-22       Impact factor: 5.640

Review 3.  Potential Use of Bacillus coagulans in the Food Industry.

Authors:  Gözde Konuray; Zerrin Erginkaya
Journal:  Foods       Date:  2018-06-13

4.  Microbiological Safety and the Management of Microbial Resources in Artisanal Foods and Beverages: The Need for a Transdisciplinary Assessment to Conciliate Actual Trends and Risks Avoidance.

Authors:  Vittorio Capozzi; Mariagiovanna Fragasso; Pasquale Russo
Journal:  Microorganisms       Date:  2020-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.